Avalo Therapeutics designates Series C-1 non-voting convertible preferred stock

Avalo Therapeutics' board established a new series of preferred stock with an initial stated value of $5,796.93 per share, convertible to common stock. The offering is led by Commodore Capital Master LP and provides the company with additional capital financing options.